A large Australian study has given a name and a clinical profile to something many patients have long experienced without explanation: a form of depression rooted not in serotonin imbalance but in the body's disrupted sense of time. Affecting roughly one in four people with severe or recurrent depression, this circadian subtype resists the medications most commonly prescribed, yet responds to treatments that realign the internal clock. The finding, drawn from over 10,000 participants, does not reveal a new suffering — it illuminates one that has quietly accumulated treatment failures, side eff
Researchers identify 'circadian depression' subtype affecting 25% of severe cases
People with circadian depression experience earlier symptom onset, more severe symptoms including higher suicidal ideation, and often face treatment failures from inappropriate initial therapy.
Depression is not a uniform illness
Mark
So this is saying that one in four people with severe depression have been getting the wrong first-line treatment?
Mimi
Not wrong exactly, but less effective for them. Standard SSRIs work well for many people. For this quarter, circadian-targeted approaches—light therapy, melatonin—work better. The problem is doctors don't know to look for it yet.
Luke
How confident are we in that 25% figure? Is it 25% of severe depression specifically, or depression broadly?
Mimi
The study looked at people with severe, recurrent, or persistent depression. So it's not the whole depression population—it's the harder cases. That matters.
Mark
And these people get sicker earlier and have more suicidal thoughts?
Mimi
Yes. Earlier onset, more severe symptoms overall, higher suicidal ideation. They also carry genetic risk for other conditions—inflammation, heart problems, ADHD.
Luke
But we don't know yet if the circadian treatment actually prevents those worse outcomes, right? Or if it just treats the depression better?
Mimi
That's fair. The study shows circadian-targeted treatments work better for the depression itself. Whether that changes the trajectory of suicidality or other comorbidities—that would need follow-up research.
Mark
So what does a clinician actually do differently tomorrow?
Mimi
Ask about sleep patterns, seasonal mood changes, whether someone's a night owl. If those fit, try light therapy or melatonin before or alongside SSRIs. It's not complicated, just different.
Luke
And if someone's already been on an SSRI for months with no improvement?
Mimi
That's when this matters most. It gives them and their doctor a reason to try something else, something with better odds for their particular biology.
The Pulse
- A quarter of severe depression cases may have been systematically mismatched with first-line treatments for years, generating avoidable failures and side effects.
- People with circadian depression face an earlier and harder illness — younger onset, more intense symptoms, higher rates of suicidal ideation, and genetic vulnerabilities spanning inflammation and neurodevelopment.
- The standard clinical reflex of prescribing SSRIs first is precisely what fails this subtype, yet the alternatives — light therapy, melatonin, clock-targeted medications — already exist and show better results.
- Researchers at the University of Sydney have now mapped the symptom cluster and genetic markers that make this subtype identifiable before the wrong treatment is tried.
- The clearest urgency falls on young patients: every failed SSRI trial is time lost in recovery, and earlier recognition could redirect them toward treatments that actually work.
A large Australian study has given a name and a clinical profile to something many patients have long experienced without explanation: a form of depression rooted not in serotonin imbalance but in the body's disrupted sense of time. Affecting roughly one in four people with severe or recurrent depression, this circadian subtype resists the medications most commonly prescribed, yet responds to treatments that realign the internal clock. The finding, drawn from over 10,000 participants, does not reveal a new suffering — it illuminates one that has quietly accumulated treatment failures, side effects, and lost years, particularly among the young.
Researchers at the University of Sydney have identified a distinct depression subtype — one that resists the medications most doctors prescribe first. Published in the British Journal of Psychiatry and drawn from clinical and genetic data on more than 10,000 Australians, the study found that roughly one in four people with severe, recurrent, or long-lasting depression fit a profile rooted in circadian rhythm disruption rather than serotonin dysregulation.
People with circadian depression share a recognizable pattern: seasonal mood shifts, sleeping longer when ill, waking unrefreshed, and a tendency toward night-owl rhythms. Critically, they show resistance to SSRIs and SNRIs — the antidepressants that anchor treatment worldwide — yet respond meaningfully to light exposure, melatonin, and medications that target the brain's internal clock. Lead author Dr. Emiliana Tonini framed the stakes plainly: understanding subtypes means getting people to effective treatment sooner.
The human cost is not abstract. Those with this subtype tend to fall ill earlier in life, experience more severe symptoms including higher rates of suicidal ideation, and carry elevated genetic risk for inflammatory, cardiovascular, and neurodevelopmental conditions. Co-senior author Dr. Jacob Crouse urged clinicians to reach for circadian-targeted treatments earlier when the presentation warrants it. Ian Hickie, co-director of the Brain and Mind Centre, was direct about what happens otherwise: failed treatments accumulate, side effects compound, and young people lose irreplaceable time.
The study did not create a new problem — it named one already present in nearly 2,604 of its participants, identifiable through symptoms and genetic markers alike. What it offers clinicians is a map for earlier recognition. For patients already struggling with an antidepressant that isn't working, the message is quieter but no less important: there may be another path worth discussing.
Researchers at the University of Sydney have identified a distinct form of depression that resists the medications most doctors reach for first. Called circadian depression, it accounts for roughly one in four cases among people with severe, recurrent, or long-lasting depression—a finding that emerged from clinical and genetic analysis of more than 10,000 Australians. The discovery, published in the British Journal of Psychiatry, suggests that for millions of people, the standard treatment path may be working against them.
Circadian depression is rooted in the body's internal 24-hour clock, the same system that governs sleep and waking. People with this subtype experience a particular cluster of symptoms: their depression often follows seasonal patterns, they sleep longer when ill, they wake exhausted, and they tend toward being night owls. What sets it apart clinically is its resistance to SSRIs and SNRIs—the serotonin-based antidepressants that form the backbone of depression treatment worldwide. Yet the same people respond better to therapies that target the circadian system directly: light exposure, melatonin, and medications designed to work on the brain's clock circuits.
The research reveals something harder to live with. People with circadian depression tend to become ill earlier in life and experience more severe symptoms. They report higher rates of suicidal thoughts. They carry elevated genetic risk for inflammatory conditions, cardiovascular disease, and neurodevelopmental disorders like ADHD. Dr. Emiliana Tonini, the study's lead author from the Brain and Mind Centre, framed the finding plainly: "Depression is not a uniform illness and understanding the characteristics of different subtypes means that we can give people earlier access to treatments that will be most effective for them."
The practical consequence is stark. Young people with circadian depression are typically prescribed SSRIs as a first step, following standard protocol. For at least a quarter of them, this approach fails—or fails while generating side effects that might have been avoided. Dr. Jacob Crouse, a co-senior author, noted that clinicians should "reach for" circadian-targeted treatments much earlier when the presentation suggests them. Ian Hickie, co-director of the Brain and Mind Centre and a practicing psychiatrist, was more direct about what happens when the mismatch goes unrecognized: early treatment failures pile up, side effects accumulate, and young people lose time in their recovery.
The study did not invent a problem; it named one that was already there. Nearly 2,604 of the 10,000 participants fit the circadian depression profile. They were identifiable through their symptoms and their genetic markers. What the research offers is a map—a way for clinicians to recognize the pattern earlier and steer people toward treatments with a better chance of working. For those already struggling with an antidepressant that isn't helping, the message is simpler: speak with your doctor about your individual circumstances. There may be another path.
Notable Quotes
Understanding the characteristics of different subtypes means we can give people earlier access to treatments that will be most effective for them.— Dr. Emiliana Tonini, lead author
For at least a quarter of young people, there are better circadian-focused medical and behavioral options to help treat and manage their condition, rather than defaulting to SSRIs first.— Ian Hickie, co-director of the Brain and Mind Centre
Want the full story?
Read the original at Medical Xpress ↗
Health & Medicine